Entrada Q1 net loss $21.7M; announces second candidate ENTR-701 for DM1; IND on track for Q4 2022

Entrada Therapeutics, Inc.

2022-Q1 EPS reported -$0.69

Q1 2022 net loss of $21.7M vs $8.4M YoY; R&D expenses rose to $15.7M from $6.2M.
Cash, equivalents & marketable securities $263.9M at March 31 (down from $291.1M); runway into H2 2024.
Announced ENTR-701 as second clinical candidate for myotonic dystrophy type 1 (DM1).
On track to submit IND for ENTR-601-44 (Duchenne MD, exon 44 skipping) in Q4 2022.
Preclinical data showed durable exon 44 skipping in NHP biceps for at least 12 weeks after single dose of ENTR-601-44.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.